BR112021007995A2 - molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente - Google Patents

molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente Download PDF

Info

Publication number
BR112021007995A2
BR112021007995A2 BR112021007995-5A BR112021007995A BR112021007995A2 BR 112021007995 A2 BR112021007995 A2 BR 112021007995A2 BR 112021007995 A BR112021007995 A BR 112021007995A BR 112021007995 A2 BR112021007995 A2 BR 112021007995A2
Authority
BR
Brazil
Prior art keywords
antibody molecule
tnfr2
antibody
cells
nucleotide sequence
Prior art date
Application number
BR112021007995-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Björn Frendéus
Ingrid Teige
Linda Mårtensson
Petra Holmkvist
Monika SEMMRICH
Original Assignee
Bioinvent International Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International Ab filed Critical Bioinvent International Ab
Publication of BR112021007995A2 publication Critical patent/BR112021007995A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112021007995-5A 2018-11-01 2019-11-01 molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente BR112021007995A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18203993.3 2018-11-01
EP18203993 2018-11-01
PCT/EP2019/080004 WO2020089474A1 (en) 2018-11-01 2019-11-01 Novel antagonistic anti tnfr2 antibody molecules

Publications (1)

Publication Number Publication Date
BR112021007995A2 true BR112021007995A2 (pt) 2021-08-10

Family

ID=64109794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007995-5A BR112021007995A2 (pt) 2018-11-01 2019-11-01 molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente

Country Status (11)

Country Link
US (2) US12441805B2 (https=)
EP (1) EP3873936A1 (https=)
JP (2) JP7646542B2 (https=)
KR (1) KR20210087029A (https=)
CN (3) CN118702818A (https=)
AU (1) AU2019372184A1 (https=)
BR (1) BR112021007995A2 (https=)
CA (1) CA3117864A1 (https=)
IL (1) IL282715A (https=)
MX (1) MX2021005150A (https=)
WO (1) WO2020089474A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529010A (ja) 2020-06-12 2023-07-06 ナンチン リーズ バイオラブス カンパニー，リミティド Ｔｎｆｒ２に結合する抗体およびその用途
US20240043551A1 (en) * 2020-12-11 2024-02-08 Adlai Nortye Biopharma Co., Ltd. Anti-tnfr2 antibody and application thereof
JP2024502035A (ja) * 2020-12-31 2024-01-17 ノヴァロック バイオセラピューティクス， リミテッド Ｔｎｆｒ２に対する抗体およびそれの使用
AU2022212842A1 (en) * 2021-01-29 2023-08-31 Shandong Simcere Biopharmaceutical Co., Ltd. Humanized antibody against tnfr2 and use thereof
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
CN116333123A (zh) * 2021-12-22 2023-06-27 宝船生物医药科技(上海)有限公司 抗tnfr2抗体及其用途
CN119591711B (zh) * 2024-11-12 2026-01-13 澳门大学 一种抑制性tnfr2单域抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
PL2953634T3 (pl) 2013-02-07 2021-11-22 The General Hospital Corporation Sposoby namnażania lub zubożania limfocytów t-regulatorowych
DK3169341T3 (da) 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
WO2016156291A1 (en) * 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
EP3294773A1 (en) * 2015-05-15 2018-03-21 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CN114605548A (zh) * 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
CA3023930C (en) * 2016-05-13 2025-09-23 The General Hospital Corporation TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY
ES2941972T3 (es) * 2016-06-22 2023-05-29 Univ Paris Val De Marne Prevención o tratamiento de la recaída de neoplasias malignas hematológicas mediante un antagonista de TNFR2

Also Published As

Publication number Publication date
JP2022512905A (ja) 2022-02-07
CN118667024A (zh) 2024-09-20
CN118702818A (zh) 2024-09-27
US12441805B2 (en) 2025-10-14
WO2020089474A1 (en) 2020-05-07
EP3873936A1 (en) 2021-09-08
MX2021005150A (es) 2021-07-15
KR20210087029A (ko) 2021-07-09
CA3117864A1 (en) 2020-05-07
CN112955469A (zh) 2021-06-11
WO2020089474A8 (en) 2021-06-24
JP2025022888A (ja) 2025-02-14
US20220073634A1 (en) 2022-03-10
US20250388690A1 (en) 2025-12-25
JP7646542B2 (ja) 2025-03-17
AU2019372184A1 (en) 2021-05-27
CN112955469B (zh) 2024-08-06
IL282715A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
US20250066492A1 (en) Agonistic anti tnfr2 antibody molecules
US20250388690A1 (en) Novel antagonistic anti-tnfr2 antibodies
US20230058227A1 (en) Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
RU2829587C2 (ru) Новые молекулы антагонистических анти-tnfr2-антител
HK40109442A (zh) 新型拮抗性抗tnfr2抗体分子
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
HK40050308B (zh) 新型拮抗性抗tnfr2抗体分子
HK40128816A (zh) 新颖激动性抗tnfr2抗体分子
HK40050308A (en) Novel antagonistic anti tnfr2 antibody molecules
HK40129120A (zh) 新颖激动性抗tnfr2抗体分子
RU2816531C2 (ru) Комбинации антител для лечения рака у конкретных пациентов
HK40053328B (zh) 新颖激动性抗tnfr2抗体分子

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]